Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q5VYS8

UPID:
TUT7_HUMAN

ALTERNATIVE NAMES:
Zinc finger CCHC domain-containing protein 6

ALTERNATIVE UPACC:
Q5VYS8; Q5H9T0; Q5VYS5; Q5VYS7; Q658Z9; Q659A2; Q6MZJ3; Q8N5F0; Q96N57; Q96NE8; Q9C0F2; Q9H8M6

BACKGROUND:
TUT7, with its alternative name Zinc finger CCHC domain-containing protein 6, is integral in global mRNA decay, microRNA-induced gene silencing, and microRNA biogenesis through its uridylyltransferase activity. It shapes the maternal transcriptome in oocytes and regulates miRNA precursors, including let-7, by uridylation, preventing their processing and leading to degradation. TUT7, alongside TUT4, restricts retrotransposition of LINE-1, highlighting its multifaceted biological roles.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifunctional role of Terminal uridylyltransferase 7 offers a promising avenue for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.